Table 4.

Goodness of fit of the simulations to the real experimental measurements under drug treatments

	Control	EGFR	Control	DNA damage	Control	Both
	input	inhibitor	input	stimuli	input	drugs
AKT	0.64	0.81	–0.40	–0.54	0.75	0.93
ERK	0.32	0.40	–0.30	–0.39	0.19	0.23
S6	0.53	0.86	0.42	0.57	0.52	0.89
S6K	0.49	0.84	0.35	0.66	0.58	0.96
4EBP1	0.67	0.67	–0.33	-0.33	0.92	0.92
BIM	0.32	0.72	0.35	0.65	–0.15	–0.38
BID	0.30	0.37	0.03	0.03	0.16	0.16
JNK	0.02	–0.07	–0.47	–0.58	–0.06	0.01
p53	–0.04	–0.45	0.21	0.83	0.01	–0.09
CABL	–0.45	–0.52	0.04	0.55	0.21	0.78
CHK	–0.12	–0.18	–0.25	–0.28	–0.30	–0.69
CDC25	0.29	0.23	0.15	0.33	0.18	0.64
Casp8	0.06	–0.06	0.14	0.72	0.26	0.68
SMAC	–0.05	0.08	–0.71	–0.87	0.48	0.99

For example, the second column is the correlation coefficients between the simulations using control input (row 1 in Table 3) and the biological measurements treated with the drug that targets EGFR